Source: http://www.google.co.uk/patents/US5614223
Timestamp: 2013-05-24 09:46:17
Document Index: 360301290

Matched Legal Cases: ['in fine', 'in fine', 'in fine', 'in fine', 'in fine', 'in fine', 'in fine', 'in fine', 'in fine', 'in fine']

Patent US5614223 - Intraoral medicament-releasing device - Google PatentsSearch Images Maps Play YouTube News Gmail Drive More »Advanced Patent Search | Web History | Sign inAdvanced Patent SearchPatentsDisclosed are controlled rate-release devices for releasing a pharmaceutically active agent into the oral cavity by the dissolving action of the saliva, a process of preparing such devices and methods of preventing/treating conditions/diseases in a mammal by delivering a pharmaceutically active substance...http://www.google.co.uk/patents/US5614223?utm_source=gb-gplus-sharePatent US5614223 - Intraoral medicament-releasing devicePublication numberUS5614223 APublication typeGrantApplication number08/503,202Publication date25 Mar 1997Filing date17 Jul 1995Priority date4 May 1992InventorsTibor SiposOriginal AssigneeDigestive Care Inc.U.S. Classification424/489424/490424/486424/435424/497International ClassificationA61K6/00A61K9/00A61K8/11A61K9/16A61K9/52A61Q11/00Cooperative ClassificationA61Q11/00A61K6/00A61K2800/412A61K9/0063A61K8/11European ClassificationA61K8/11A61Q11/00A61K6/00A61K9/00M18EReferencesPatent Citations (11)Non-Patent Citations (12)Referenced by (19)External LinksUSPTOUSPTO AssignmentEspacenetIntraoral medicament-releasing deviceUS 5614223 AAbstract Disclosed are controlled rate-release devices for releasing a pharmaceutically active agent into the oral cavity by the dissolving action of the saliva, a process of preparing such devices and methods of preventing/treating conditions/diseases in a mammal by delivering a pharmaceutically active substance into the oral cavity.
What is claimed is: 1. A controlled rate-release device for attachment to teeth in the oral cavity capable of releasing a pharmaceutically active agent at a constant rate comprising: (a) a plurality of discrete granules being in the particle size range of from about 850 to about 1,700 microns and consisting essentially of (1) of from about 1 to about 84% w/w of a pharmaceutically active agent in finely divided power form imbedded in a solid non-erodable co-polymeric structure of (2) 35 to about 15% w/w of 2-hydroxyethyl methacrylate/methyl methacrylate copolymer which comprises from about 40 to about 60 mole % of 2-hydroxyethyl methacrylate and from about 60 to about 40% mole of methyl methacrylate, wherein in each of said granules said co-polymeric structure surrounds the finely divided particles of said pharmaceutically acceptable active agent, and wherein said granules are compressed into dosage forms in the shape of tablets, capsules, globules, half-football shapes, veneers or thick films and are coated with (b) a non-erodable diffusion rate-controlling membrane consisting essentially of from about 20 to about 40 mole % of 2-hydroxyethyl methacrylate and from about 60 to about 80 mole % of methyl methacrylate.
11. A method of preventing dental caries development in a mammal by administering an effective amount of F.sup.- to said mammal that is released at a constant rate from a controlled rate-release device capable of releasing said F.sup.- into the oral cavity, said controlled rate-release device comprising: (a) a plurality of discrete granules being in the particle size range of from about 850 to about 1,700 microns and consisting essentially of (1) of from about 1 to about 84% w/w of a F.sup.- containing agent in finely divided power form imbedded in a solid non-erodable co-polymeric structure of from 35 to about 15% w/w of 2-hydroxyethyl methacrylate/methyl methacrylate co-polymer which comprises from about 40 to about 60 mole % of 2-hydroxyethyl methacrylate and from about 60 to about 40 mole % of methyl methacrylate wherein in each of said granules said co-polymeric structure surrounds the finely divided particles of said F.sup.- containing agent, and wherein said granules are compressed into dosage forms in the shape of tablets, capsules, globules, half-football shapes, veneers or thick films and are coated with (b) a non-erodable rate-controlling co-polymer membrane consisting essentially of from about 20 to about 40 mole % of 2-hydroxyethyl methacrylate and from about 60 to about 80 mole % of methyl methacrylate.
12. A method of preventing/treating incipient carious lesions around orthodontic appliances by providing an effective amount of F.sup.- that is released at a constant rate from a controlled rate-release device installed into the oral cavity, said controlled rate-release device capable of releasing said F.sup.- into the oral cavity, said controlled rate-release device comprising: (a) a plurality of discrete granules being in the particle size range of from about 850 to about 1,700 microns and consisting essentially of (1) from about 1 to about 84% w/w of said F- containing agent in finely divided power form imbedded in a solid non-erodable co-polymeric structure of from about 35 to about 15% w/w of 2-hydroxyethyl methacrylate/methyl methacrylate co-polymer which comprises from about 40 to about 60 mole % of 2-hydroxyethyl methacrylate and from about 60 to about 40 mole % of methyl methacrylate wherein in each of said granules said co-polymeric structure surrounds the finely divided particles of said F.sup.- containing agent, and wherein said granules are compressed into dosage forms in the shape of tablets, capsules, globules, half-football shapes, veneers or thick films and are coated with (b) a non-erodable rate-controlling co-polymer membrane consisting essentially of from about 20 to about 40 mole % of 2-hydroxyethyl methacrylate and from about 60 to about 80 mole % of methyl methacrylate.
15. A method of preventing periodontal disease in a mammal by administering an effective amount of a collagenolytic enzyme inhibitor to said mammal that is released at a constant rate from a controlled rate-release device capable of releasing said collagenolytic enzyme inhibitor into the oral cavity, said controlled rate-release device comprising (a) a plurality of discrete granules being in the particle size range of from about 850 to about 1,700 microns and consisting essentially of (1) from about 1 to about 84% w/w of said collagenolytic enzyme inhibitor in finely divided power form imbedded in a solid non-erodable co-polymeric structure of from about 35 to about 15% w/w of 2-hydroxyethyl methacrylate/methyl methacrylate co-polymer which comprises from about 40 to about 60 mole % of 2-hydroxyethyl methacrylate and from about 60 to about 40 mole % of methyl methacrylate wherein in each of said granules said co-polymeric structure surrounds the finely divided particles of said collagenolytic enzyme inhibitor, and wherein said granules are compressed into dosage forms in the shape of tablets, capsules, globules, half-football shapes, veneers or thick films and are coated with (b) a non-erodable rate-controlling co-polymer membrane consisting essentially of from about 20 to about 40 mole % of 2-hydroxyethyl methacrylate and from about 60 to about 80 mole % of methyl methacrylate.
18. A method of treating testosterone deficiency in a mammal by administering an effective amount of testosterone that is released at a constant rate from a controlled rate-release device capable of releasing said testosterone into the oral cavity, said controlled rate-release device comprising: (a) a plurality of discrete granules being in the particle size range of from about 850 to about 1,700 microns and consisting essentially of (1) from about 1 to about 84% w/w of said testosterone in finely divided power form imbedded in a solid non-eroable co-polymeric structure of from about 35 to about 15% w/w of 2-hydroxyethyl methacrylate/methyl methacrylate co-polymer which comprises from about 40 to about 60 mole % of 2-hydroxyethyl methacrylate and from about 60 to about 40 mole % of methyl methacrylate wherein in each of said granules said co-polymeric structure surrounds the finely divided particles of said testosterone, and wherein said granules are compressed into dosage forms in the shape of tablets, capsules, globules, half-football shapes, veneers or thick films and are coated with (b) a non-erodable rate-controlling co-polymer membrane consisting essentially of from about 20 to about 40 mole % of 2-hydroxyethyl methacrylate and from about 60 to about 80 mole % of methyl methacrylate.
19. A method of treating osteoporosis deficiency in a mammal by administering an effective amount of calcitonin that is released at a constant rate from a controlled rate-release device capable of releasing said calcitonin into the oral cavity, said controlled rate-release device comprising: (a) plurality of discrete granules being in the particle size range of from about 850 to about 1,700 microns and consisting essentially of (1) from about 1 to about 84% w/w of said calcitonin in finely divided power form imbedded in a solid non-erodable co-polymeric structure of from about 35 to about 15% w/w of 2-hydroxyethyl methacrylate/methyl methacrylate co-polymer which comprises from about 40 to about 60 mole % of 2-hydroxyethyl methacrylate and from about 60 to about 40 mole % of methyl methacrylate wherein in each of said granules said co-polymeric structure surrounds the finely divided particles of said calcitonin, and wherein said granules are compressed into dosage forms in the shape of tablets, capsules, globules, half-football shapes, veneers or thick films and are coated with (b) a non-erodable rate-controlling co-polymer membrane consisting essentially of from about 20 to about 40 mole % of 2-hydroxyethyl methacrylate and from about 60 to about 80 mole % of methyl methacrylate.
20. A method of suppressing appetite in a mammal by administering an effective amount of cholecystokinin that is released at a constant rate from a controlled rate-release device capable of releasing said cholecystokinin into the oral cavity, said controlled rate-release device comprising: (a) a plurality of discrete granules being in the particle size range of from about 850 to about 1,700 microns and consisting essentially of (1) from about 1 to about 84% w/w of said cholecystokinin in finely divided power form imbedded in a solid non-erodable co-polymeric structure of from about 35 to about 15% w/w of 2-hydroxyethyl methacrylate/methyl methacrylate co-polymer which comprises from about 40 to about 60 mole % of 2-hydroxyethyl methacrylate and from about 60 to about 40 mole % of methyl methacrylate wherein in each of said granules said co-polymeric structure surrounds the finely divided particles of said cholecystokinin, and wherein said granules are compressed into dosage forms in the shape of tablets, capsules, globules, half-football shapes, veneers or thick films and are coated with (b) a non-erodable rate-controlling co-polymer membrane consisting essentially of from about 20 to about 40 mole % of 2-hydroxyethyl methacrylate and from about 60 to about 80 mole % of methyl methacrylate.
21. A method of suppressing craving for drugs in a mammal by administering an effective amount of methodone hydrochloride that is released at a constant rate from a controlled rate-release device capable of releasing said methodone hydrochloride into the oral cavity, said controlled rate-release device comprising: (a) a plurality of discrete granules being in the particle size range of from about 850 to about 1,700 microns and consisting essentially of (1) from about 1 to about 84% w/w of said methodone hydrochloride in finely divided power form imbedded in a solid non-erodable co-polymeric structure of from about 35 to about 15% w/w of 2-hydroxyethyl methacrylate/methyl methacrylate co-polymer which comprises from about 40 to about 60 mole % of 2-hydroxyethyl methacrylate and from about 60 to about 40 mole % of methyl methacrylate wherein in each of said granules said co-polymeric structure surrounds the finely divided particles of said methodone hydrochloride, and wherein said granules are compressed into dosage forms in the shape of tablets, capsules, globules, half-football shapes, veneers or thick films and are coated with (b) a non-erodable rate-controlling co-polymer membrane consisting essentially of from about 20 to about 40 mole % of 2-hydroxyethyl methacrylate and from about 60 to about 80 mole % of methyl methacrylate.
22. A method of treating yeast infection in a mammal by administering an effective amount of nystatin that is released at a constant rate from a controlled rate-release device capable of releasing said nystatin into the oral cavity, said controlled rate-release device comprising: (a) a plurality of discrete granules being in the particle size range of from about 850 to about 1,700 microns and consisting essentially of (1) from about 1 to about 84% w/w of said nystatin in finely divided power form imbedded in a solid non-erodable co-polymeric structure of from about 35 to about 15% w/w of 2-hydroxyethyl methacrylate/methyl methacrylate co-polymer which comprises from about 40 to about 60 mole % of 2-hydroxyethyl methacrylate and from about 60 to about 40 mole % of methyl methacrylate wherein in each of said granules said co-polymeric structure surrounds the finely divided particles of said nystatin, and wherein said granules are compressed into dosage forms in the shape of tablets, capsules, globules, half-football shapes, veneers or thick films and are coated with (b) a non-erodable rate-controlling co-polymer membrane consisting essentially of from about 20 to about 40 mole % of 2-hydroxyethyl methacrylate and from about 60 to about 80 mole % of methyl methacrylate.
23. A method of inhibiting metastasis of tumors in a mammal by administering an effective amount of octreotide acetate that is released at a constant rate from a controlled rate-release device capable of releasing said octreotide acetate into the oral cavity, said controlled rate-release device comprising: (a) a plurality of discrete granules being in the particle size range of from about 850 to about 1,700 microns and consisting essentially of (1) from about 1 to about 84% w/w of said octreotide acetate in finely divided power form imbedded in a solid non-erodable co-polymeric structure of from about 35 to about 15% w/w of 2-hydroxyethyl methacrylate/methyl methacrylate co-polymer which comprises from about 40 to about 60 mole % of 2-hydroxyethyl methacrylate and from about 60 to about 40 mole % of methyl methacrylate wherein in each of said granules said co-polymeric structure surrounds the finely divided particles of said octreotide acetate, and wherein said granules are compressed into dosage forms in the shape of tablets, capsules, globules, half-football shapes, veneers or thick films and are coated with (b) a non-erodable rate-controlling co-polymer membrane consisting essentially of from about 20 to about 40 mole % of 2-hydroxyethyl methacrylate and from about 60 to about 80 mole % of methyl methacrylate.
______________________________________NaF Content       55.99 NaF-25.33 mg F-ionDimensions in mm  8.4(l) Average Weight    88.1 .+-. 0.5 mgF-ion Release     0.09 mg per 24 hours______________________________________
The core preparation consisted of mixing the 50:50 mole % HEMA:MMA co-polymer with sodium fluoride in a blender. The mixture was granulated to a paste, passed through a sieve to obtain granules. The granules were dried in an oven under a stream of warm and dry air, not exceeding 80 residual solvent odor was detected, the granules were dried in a desiccator under vacuum. The granules were reduced in size using a centrifugal grinding mill, and compressed into cores of desired shape.
1.1 This method used to determine the average daily fluoride (F.sup.-) release rate from intraoral fluoride-releasing devices (IFRD) designed to passively release controlled (constant) amounts of F.sup.- into the oral cavity for at least six months.
2.1 An IFRD is placed in a plastic jar and a diffusion buffer solution is added. The jar is mounted in a rotator and the entire apparatus is placed in a thermostated incubator. The diffusion buffer simulates the pH and ionic strength of saliva and contains the major salivary ions (except calcium). The amount of F.sup.- released by the IFRD into the diffusion buffer is assayed potentiometrically with a F.sup.- ion specific electrode and an Orion
3.1 Due to the inherent reactivity of F.sup.- ion with glass, all F.sup.- solutions were mixed, stored and dispensed from plastic labware.
3.2 Ionic activity is a function of temperature. Whenever laboratory temperature varied by more than 2 standardization conditions, standardization was repeated.
3.3 Since the F.sup.- ion specific electrode responds to hydroxide (OH.sup.-) ion, but does not respond to HF, all F.sup.- measurements were carried out in between pH 5.0 to 5.5 to minimize erroneously high readings due to OH.sup.- ion contribution or to the formation of HF [Ka.sub.(HF) =3.5.multidot.10.sup.-3 ].
3.4 A total ionic strength adjusting buffer (TISAB-II) Orion in equal proportions with all F.sup.- solutions to provide a constant background ionic strength, to decomplex bound F.sup.- and to adjust solution pH between 5.0 and 5.5.
4.1 Precision: Measured concentration of F.sup.- is reproducible to .+-.2% based on repeated (n=10) measurements of one sample.
4.2 Accuracy: Based on repeated (n=10) measurements of a 5.0 ppm F.sup.- standard solution, the accuracy is .+-.4%.
5.1 Orion
5.3 Orion
5.5 Baxter equivalent.
5.6 Baxter equivalent.
5.8.1 Solution A: dissolve 1.24 g NaH.sub.2 PO.sub.4.H.sub.2 O, 115.13 g KCl and 2.0 g NaN.sub.3 in 600 ml DDW.
5.9 Diffusion buffer solution: Prior to use, diffusion buffer stock solution is diluted [5.8.3.] 10-fold (100 ml stock solution diluted with 900 ml DDW) and pH adjusted to 7.0 if required. The diffusion buffer system has a pK.sub.a 7.2 with ΔpH/ bactericidal.
6.1 Unit Performance Check: according to Orion
6.3 F.sup.- Calibration: according to Orion two-point calibration with 1.00 ppm F.sup.- and 10.0 ppm F.sup.- standard solutions is used.
7.1 IFRD Selection/Inspection: Devices are randomly selected and visually inspected under 10 other membrane imperfections) until six satisfactory devices are obtained.
7.2 IFRD F.sup.- Release: Each inspected device is weighed to the nearest 0.1 mg and placed individually into a 120 ml plastic jar which was pre-rinsed with diffusion buffer solution. Jar and lid are labelled with an identifying number. 100 ml of diffusion buffer [5.9.] is added to each jar. Each jar is mounted on the platter of an end-over-end rotator (Fischer Scientific Chemistry Mixer) at using two large rubber bands and the rotator is placed into a thermostated incubator.
7.3 Diffusion Buffer Blank: A diffusion buffer blank jar to correct for the background amount of F.sup.- was prepared by adding 100 ml of diffusion buffer [5.9] to a jar without an IFRD. This jar was mounted with the IFRD sample jars [7.2.].
7.4 IFRD Buffer Change: Jars [7.2., 7.3.] from the incubator were removed on each Monday and Friday and a 10 ml aliquot of each buffer solution was decanted into separate, prelabeled 15 ml plastic tubes for subsequent F.sup.- analysis. The remainder of the diffusion buffer was discarded. 100 ml of fresh diffusion buffer [5.9.] was added to all jars and replaced in the incubator. The diffusion buffer changes were repeated until the F.sup.- release had ceased. Date and time of buffer change were recorded to nearest half hour and rotation (8 rpm) was continued.
7.5 F.sup.- measurements: 2.0 ml of each diffusion buffer aliquot [7.4.] was transferred into a 30 ml plastic cup and 2.0 ml of TISAB solution was added. A magnetic stirring bar was inserted and stirred gently. A previously standardized F.sup.- ion specific electrode was placed into the stirred sample and the F.sup.- concentration (ppm) was measured to the nearest 0.01 ppm F.sup.-. When the meter reading was stable, the F.sup.- concentration was recorded. The electrode was rinsed with distilled water and blotted dry with a soft tissue. If the laboratory temperature varied by more than 2 F.sup.- electrode was re-standardized.
8.1 The total amount (mg) of F.sup.- contained within each jar was calculated by multiplying the meter reading (ppm F.sup.31 ) of each sample aliquot [7.2.] by the volume of diffusion buffer in liters (L). [ppm=mg F.sup.- /L]
8.2 The net amount (mg) of F.sup.- released from the IFRD into the diffusion buffer was calculated by subtracting the background amount of F.sup.- from the total amount of F.sup.- present in each sample of diffusion buffer.
8.3 The average daily F.sup.- release rate was calculated as the net amount of F.sup.- released (mg) into the buffer divided by the number of elapsed days between buffer changes. (Rate=mg F.sup.- /day).
The present invention is also directed to a method of preventing dental caries (enamel and dentinal), development of incipient carious lesions (white spot lesions) around orthodontic appliances in the oral cavity in a mammal by administering an effective amount of F.sup.- to said mammal that is released at a constant rate from the slow, controlled rate-release device which is placed into the oral cavity. Such release should be from about 0.01 to about 0.15 mg/day of F.sup.- from about 80 to about 2530 days.
There is also concern that daily use of a high fluoride concentration can result in inadvertent ingestion of high doses of F.sup.- that causes fluoride toxicity and the development of gastric ulcers.
An Intraoral Fluoride Releasing System (IFRS) consisting of a retainer containing a slow-releasing sodium fluoride pellet (IFRD), provides a constant, low level (0.07 mg daily) source of fluoride. After installation of the F.sup.- releasing device into the oral cavity by a dentist, the device releases fluoride automatically and requires no compliance on the part of the patient. These patients will be wearing two IFRD's and, therefore, will be receiving 0.14 mg F.sup.- daily (or 0.31 mg as NaF). There is an abundance of data to show that 0.14 mg F.sup.- daily is non-toxic and non-irritating.
Patent CitationsCited PatentFiling datePublication dateApplicantTitleUS362490926 May 19707 Dec 1971Commerce DriveTeeth gripping medicament applicator for treatment of teeth and/or gumsUS36884067 Aug 19705 Sep 1972Frank W. HindsleyApparatus for and method of applying decay retardant compositions to teethUS402055821 Jul 19753 May 1977Societe SodermecBuccal implant for administering solubilizable productsUS417532626 Oct 197727 Nov 1979Forsyth Dental Infirmary For ChildrenHollow-fiber devices for and a method of the treament and diagnosis of oral diseasesUS46613503 Jul 198628 Apr 1987Kitasato KenkyushoDental vaccine for inhibiting periodontitisUS46815446 Aug 198521 Jul 1987Anthony; Albert J.Oral pack retention systemUS468588326 Jul 198511 Aug 1987Jernberg; Gary R.Local delivery of chemotherapeutic agents for the treatment of periodontal diseaseUS48370306 Oct 19876 Jun 1989American Cyanamid CompanyNovel controlled release formulations of tetracycline compoundsUS49199398 Jul 198824 Apr 1990Pharmetrix CorporationPeriodontal disease treatment systemUS493541128 Oct 198719 Jun 1990The Research Foundation Of State University Of New YorkNon-antibacterial tetracycline compositions possessing anti-collagenolytic properties and methods of preparing and using sameEP0184389A228 Nov 198511 Jun 1986Lederle (Japan) Ltd.Composition stably containing minocycline for treating periodontal diseasesNon-Patent CitationsReference1D. Mirth et al, Clinical Evaluation of an Introral Device for the Controlled Release of Fluoride, JADA, V. 105, Nov. 1982, pp. 781 797.2D. Mirth et al, Clinical Evaluation of an Introral Device for the Controlled Release of Fluoride, JADA, V. 105, Nov. 1982, pp. 781-797.3D. Mirth et al, Development and In Vitro Evaluation of an Intra Oral Controlled Release Delivery System for Chlorhexidine, J. Dent. Res., Aug. 1989.4D. Mirth et al, Development and In Vitro Evaluation of an Intra-Oral Controlled-Release Delivery System for Chlorhexidine, J. Dent. Res., Aug. 1989.5H. K. Morisaki et al, local Ofloxacin Delivery Using a Controlled Release Insert (PF01) in the Human Periodontal Pocket, J. Periodont. Res. 1990, 25:1:5.6H. K. Morisaki et al, local Ofloxacin Delivery Using a Controlled-Release Insert (PF01) in the Human Periodontal Pocket, J. Periodont. Res. 1990, 25:1:5.7M. Friedman, Fluoride Uptake by Powdered Human Enamel Treated with Prolonged Active Fluoride Pellets in Vitro, Arch. Oral. Biol. V. 26, pp. 131 134, 1981.8M. Friedman, Fluoride Uptake by Powdered Human Enamel Treated with Prolonged Active Fluoride Pellets in Vitro, Arch. Oral. Biol. V. 26, pp. 131-134, 1981.9Southern Research Institute Bulletin, Winter 1979, V. 32, No. 1, pp. 16 22.10Southern Research Institute Bulletin, Winter 1979, V. 32, No. 1, pp. 16-22.11T. Larson, In Vitro Release of Doxycycline from Bioabsorbable Materials and Strips, J. Periodontal Research, 1990; 61; 30 34.12T. Larson, In Vitro Release of Doxycycline from Bioabsorbable Materials and Strips, J. Periodontal Research, 1990; 61; 30-34.Referenced byCiting PatentFiling datePublication dateApplicantTitleUS600779516 Jan 199728 Dec 1999Gillette Canada Inc.Compositions including particles including degradable material and anti-microbial agentUS632599124 Aug 19994 Dec 2001Draheim Susan E.Methods and compositions for treating periodontal disease with an inhibitor of secretory phospholipase A2US659286030 May 200015 Jul 2003Soluble Systems, LlcComposition and applicator for topical substance deliveryUS725042812 Feb 200431 Jul 2007Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A.Cetylpyridinium salt of an anti-inflammatory agent and pharmaceutical compositions containing itUS745286810 Mar 200618 Nov 2008Indevus Pharmaceuticals, Inc.Controlled release formulations of octreotideUS775931211 Jul 200820 Jul 2010Endo Pharmaceuticals Solutions Inc.Delivery of dry formulations of octreotideUS776665830 Nov 20043 Aug 2010Align Technology, Inc.Systems and methods for intra-oral diagnosisUS780377329 Sep 200828 Sep 2010Endo Pharmaceuticals Solutions Inc.Controlled release formulations of octreotideUS794750831 Oct 200724 May 2011Align Technology, Inc.Systems and methods for intra-oral diagnosisUS796033524 Jun 200914 Jun 2011Endo Pharmaceuticals Solutions Inc.Octreotide implant having a release agent and uses thereofUS806265217 Jun 200522 Nov 2011Endo Pharmaceuticals Solutions Inc.Compositions and methods for treating precocious pubertyUS807153724 Jun 20096 Dec 2011Endo Pharmaceuticals Solutions Inc.Implantable device for the sustained release of a polypeptideUS817315222 Mar 20078 May 2012Auxilium Us Holdings, LlcStabilized compositions containing alkaline labile drugsUS838357729 Apr 201126 Feb 2013Endo Pharmaceuticals Solutions, Inc.Octreotide implant having a release agentWO2000044439A124 Jan 20003 Aug 2000Friedman, Mark, M.Device and method for stimulating salivationWO2003017960A121 Aug 20026 Mar 2003Bosy, AnneOral rinse for treatment or prevention of bacterial and fungal infectionWO2004072017A112 Feb 200426 Aug 2004Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A.Cetylpyridinium salt of an anti-inflammatory agent and pharmaceutical compositions containing itWO2006099288A210 Mar 200621 Sep 2006Decker, StephanieControlled release formulations of octreotideWO2011121224A229 Mar 20116 Oct 2011Universite Claude Bernard Lyon IElastic orthodontic elements that can release poorly saliva-soluble chlorhexidineRotateOriginal ImageGoogle Home - Sitemap - USPTO Bulk Downloads - Privacy Policy - Terms of Service - About Google Patents - Send FeedbackData provided by IFI CLAIMS Patent Services©2012 Google